ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
3 announcements with these filters
Concord Biotech announced successful completion of inspections by Kenya's PPB and Uganda's NDA at its Unit-II formulation facility. The milestone enhances its global regulatory footprint.
Concord Biotech received USFDA approval for Tofacitinib Tablets (5mg and 10mg). The approval targets a US$ 500 million market, strengthening the company's US pharmaceutical footprint.
Concord Biotech received USFDA approval for its Mycophenolate Mofetil Oral Suspension ANDA. This approval strengthens the company's position in the US$ 30 million U.S. market.